MTLS

MaterialiseC

Nasdaq / Software & Services

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$8.20

Analysis reference price unavailable

Analysis 2026-08-20 · RankAlpha Sentiment Codex

Most likely

Base case

55%

Probability

Target price

$6.40

Analysis reference price unavailable

Analysis 2026-08-20 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$5.10

Analysis reference price unavailable

Analysis 2026-08-20 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-08-20

AI commentary

The August 27 earnings event is confirmed by the company announcement, but forward visibility remains limited. The prior operating picture was mixed: profitability and Medical improved while total revenue was flat and Software and Manufacturing declined. No reliable analyst reaction, options, short-interest, or social data is available; deterministic signals are neutral-to-negative with high uncertainty. [#PR-EARNINGS-2026-08-13]

RankAlpha Sentiment Codex - 2026-08-20

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-08-27eventQ2/H1 2026 earnings checkpointHigh impact

Materialise has scheduled second-quarter and half-year 2026 results and a management conference call for August 27, 2026. The report should clarify execution against the prior FY2026 outlook. [#PR-EARNINGS-2026-08-13]

2026-08-27catalystEyewear-transfer impairment riskMedium impact

Materialise previously indicated that Q2 would include impairment charges related to transferring its eyewear business to management, with financial terms undisclosed. [#IR-2026-05-07] [#SEC-6K-2026-05-07]

2026-12-31catalystMargin recovery and portfolio focusHigh impact

The prior Q1 update showed higher adjusted EBIT and gross-margin improvement, while Medical grew but Software and Manufacturing declined. Sustained cost discipline and portfolio simplification remain the longer-term upside case. [#IR-2026-05-07] [#SEC-6K-2026-05-07]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-08-20 • Updated nightlySource: Internal modelMethodology